ECDC risk assessment: 2009 influenza A(H1N1) pandemic (Update 12 June 2009)
A new influenza A virus was identified by the United States CDC in April this year in samples from two Californian children and retrospectively in cases in Mexico (CDC 2009a, Fraser 2009, CDC 2009b). The new virus and the disease it caused were initially called ‘swine flu’. The basic genetic structure of the virus has been described and this information is available through publicly accessible websites (Trifonov 2009, Nava 2009). The virus has a number of genetic elements from two different types of swine influenza, but also elements originally from avian and human influenzas that were incorporated into other swine influenza viruses (Nava 2009). However, it is unclear if the specific reassortment leading to the new virus took place in pigs or humans.
Threat Assessment Brief: Implications of the further emergence and spread of the SARS CoV 2 B.1.1.529 variant of concern (Omicron) for the EU/EEA first update
2 Dec 2021 - The number of countries reporting SARS-CoV-2 Omicron variant of concern (VOC) cases continues to increase globally, with a total of 352 confirmed cases reported by 27 countries as of 16.00 on 1 December 2021, including 70 confirmed cases reported by 13 European Union and European Economic Area (EU/EEA) countries.
Threat Assessment Brief: Implications of the emergence and spread of the SARS-CoV-2 B.1.1. 529 variant of concern (Omicron) for the EU/EEA
26 Nov 2021 - A SARS-CoV-2 variant belonging to Pango lineage B.1.1.529, with a high number of S-gene mutations compared to the original virus was detected at the beginning of November 2021. On 26 November 2021 the variant was designated a variant of concern (VOC) and assigned the label Omicron by the World Health Organization (WHO).
Assessment of the current SARS-CoV-2 epidemiological situation in the EU/EEA, projections for the end-of-year festive season and strategies for response, 17th update
24 Nov 2021 - This Rapid Risk Assessment assesses the risk posed by the circulation of the Delta variant of SARS-CoV-2 between 1 December 2021 to 31 January 2022, based on modelling scenarios and projected levels of vaccination coverage.